Bone Density Decline: Tenofovir is linked to a decrease in bone mineral density, expanding the potential risk of bone challenges or fractures. In phase 3 medical trials, tenofovir presented a similar efficacy than efavirenz in procedure-naive HIV sufferers. In hepatitis B contaminated people, after a person 12 months of tenofovir https://hivhub.in/product/viropil-tablet/